EPICART
DNA methylation kit for the prediction of the response to CAR T-cell therapy.
EPICART is a risk stratification tool that employs a methylation signature that accurately predicts the treatment outcome of B-malignancy patients treated with CD19 CAR T-cell therapy.
![EPICART DNA methylation kit for the prediction of the response to CAR T-cell therapy.](/assets/epicart-de2a875533033503ed568716a88296e1d840e9cd857b03f3a044578f30f005d0.png)